Indivior Pharmaceuticals, Inc. — Income Charts
2 years of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue
$1.24B
Cost of Revenue
$246M
Gross Profit
$994M
R&D
$97M
SG&A
$634M
D&A
$10M
Operating Income
$262M
EBITDA
$272M
Interest Expense
$38M
Interest Income
$22M
Other Income/Expense
$-7M
Pretax Income
$239M
Tax Provision
$29M
Net Income
$210M
Gross Margin
80.2%
Operating Margin
21.1%
Net Margin
16.9%
Effective Tax Rate
12.1%
Deferred Tax Assets
$326M
Deferred Tax Liabilities
$1M
DTA Valuation Allowance
$55M
Tax Credit Carryforwards
$12M
NOL Carryforwards
$128M
ETR (Continuing Operations)
12.2%
ETR Federal Statutory
25.0%
ETR State + Local (pp)
0.0%
ETR Foreign Differential (pp)
8.8%
Operating Lease Cost
$12M
Revenue YoY Variation
4.3%
Income YoY Variation
589.5%